US2023242542A1PendingUtilityA1

COMPOSITIONS COMPRISING (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE

85
Assignee: BEIGENE SWITZERLAND GMBHPriority: Aug 16, 2016Filed: Mar 7, 2023Published: Aug 3, 2023
Est. expiryAug 16, 2036(~10.1 yrs left)· nominal 20-yr term from priority
Inventors:Zhiwei WangYunhang GuoGongyin ShiLai-Xi Wang
A61P 35/00Y02P20/55C07D 487/04C07B 2200/13C07B 2200/07A61K 31/519A61P 37/00A61P 29/00A61P 35/02A61P 37/02A61P 37/08C07B 2200/05A61P 35/04
85
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to pharmaceutical compositions comprising (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for the treatment of B-cell malignancies.

Claims

exact text as granted — not AI-modified
1 - 42 . (canceled) 
     
     
         43 . A pharmaceutical composition comprising:
 a) at least one pharmaceutically acceptable excipient, and   b) a means for treating a B-cell malignancy,   wherein the pharmaceutical composition comprises said means in an amount effective to treat the B-cell malignancy.   
     
     
         44 . The pharmaceutical composition according to  claim 43 , wherein the B-cell malignancy is mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), or marginal zone lymphoma (MZL). 
     
     
         45 . The pharmaceutical composition according to  claim 43 , wherein the B-cell malignancy is diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia (WM), or marginal zone lymphoma (MZL). 
     
     
         46 . The pharmaceutical composition according to  claim 43 , wherein the B-cell malignancy is a relapsed/refractory B-cell malignancy. 
     
     
         47 . The pharmaceutical composition according to  claim 43 , wherein the B-cell malignancy is relapsed/refractory mantle cell lymphoma (R/R MCL), relapsed/refractory chronic lymphocytic leukemia (R/R CLL), relapsed/refractory small lymphocytic lymphoma (R/R SLL), or relapsed/refractory Waldenstrom macroglobulinemia (R/R WM). 
     
     
         48 . The pharmaceutical composition according to  claim 43 , comprising from 40 mg to 320 mg of said means. 
     
     
         49 . The pharmaceutical composition according to  claim 43 , comprising 160 mg of said means. 
     
     
         50 . The pharmaceutical composition according to  claim 43 , comprising 320 mg of said means. 
     
     
         51 . The pharmaceutical composition according to  claim 43 , wherein the effective amount is an amount sufficient to provide a total daily dose of 320 mg of said means in one or more doses. 
     
     
         52 . The pharmaceutical composition according to  claim 43 , wherein the effective amount is an amount sufficient to provide a twice-daily dose of 160 mg of said means. 
     
     
         53 . The pharmaceutical composition according to  claim 43 , comprising from 1 wt % to 99 wt % of said means, relative to the total weight of the composition. 
     
     
         54 . The pharmaceutical composition according to  claim 43 , comprising from 1 wt % to 70 wt % of said means, relative to the total weight of the composition. 
     
     
         55 . The pharmaceutical composition according to  claim 43 , comprising from 10 wt % to 30 wt % of said means, relative to the total weight of the composition. 
     
     
         56 . A pharmaceutical composition comprising:
 a) at least one pharmaceutically acceptable excipient, and   b) an amount of a means for treating a B-cell malignancy sufficient to provide a total daily dose of 320 mg of said means,   wherein the B-cell malignancy is diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia (WM), marginal zone lymphoma (MZL), relapsed/refractory mantle cell lymphoma (R/R MCL), relapsed/refractory chronic lymphocytic leukemia (R/R CLL), relapsed/refractory small lymphocytic lymphoma (R/R SLL), or relapsed/refractory Waldenstrom macroglobulinemia (R/R WM).   
     
     
         57 . A pharmaceutical composition comprising:
 a) at least one pharmaceutically acceptable excipient, and   b) a means for treating a B-cell malignancy in a patient,   wherein the pharmaceutical composition comprises from 40 mg to 320 mg of said means.   
     
     
         58 . The pharmaceutical composition according to  claim 57 , comprising:
 a) at least one pharmaceutically acceptable excipient, and   b) a means for treating diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia (WM), or marginal zone lymphoma (MZL).   
     
     
         59 . The pharmaceutical composition according to  claim 57 , comprising:
 a) at least one pharmaceutically acceptable excipient, and   b) a means for treating mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), or marginal zone lymphoma (MZL).   
     
     
         60 . The pharmaceutical composition according to  claim 57 , comprising:
 a) at least one pharmaceutically acceptable excipient, and   b) a means for treating a relapsed/refractory B-cell malignancy in a patient.   
     
     
         61 . The pharmaceutical composition according to  claim 58 , comprising 160 mg of said means. 
     
     
         62 . The pharmaceutical composition according to  claim 58 , comprising 320 mg of said means.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.